Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance.

MLA

Pfarr, Nicole, et al. “Targeted Next-Generation Sequencing Enables Reliable Detection of HER2 (ERBB2) Status in Breast Cancer and Provides Ancillary Information of Clinical Relevance.” Genes, Chromosomes & Cancer, vol. 56, no. 4, Apr. 2017, pp. 255–65. EBSCOhost, https://doi.org/10.1002/gcc.22431.

APA

Pfarr, N., Penzel, R., Endris, V., Lier, C., Flechtenmacher, C., Volckmar, A., Kirchner, M., Budczies, J., Leichsenring, J., Herpel, E., Noske, A., Weichert, W., Schneeweiss, A., Schirmacher, P., Sinn, H., & Stenzinger, A. (2017). Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance. Genes, Chromosomes & Cancer, 56(4), 255–265. https://doi.org/10.1002/gcc.22431

Chicago

Pfarr, Nicole, Roland Penzel, Volker Endris, Clemens Lier, Christa Flechtenmacher, Anna‐Lena Volckmar, Martina Kirchner, et al. 2017. “Targeted Next-Generation Sequencing Enables Reliable Detection of HER2 (ERBB2) Status in Breast Cancer and Provides Ancillary Information of Clinical Relevance.” Genes, Chromosomes & Cancer 56 (4): 255–65. doi:10.1002/gcc.22431.